<SEC-DOCUMENT>0001213900-22-019858.txt : 20220414
<SEC-HEADER>0001213900-22-019858.hdr.sgml : 20220414
<ACCEPTANCE-DATETIME>20220414164412
ACCESSION NUMBER:		0001213900-22-019858
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220414
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220414
DATE AS OF CHANGE:		20220414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		22827844

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea158456-8k_nektarther.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:NKTR="http://nektar.com/20220414">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_NKTR_nektar.com_20220414 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20220414_20220414 -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0000906709 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-04-14to2022-04-14" name="dei:EntityCentralIndexKey">0000906709</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-14to2022-04-14" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="nktr-20220414.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-04-14to2022-04-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-14</xbrli:startDate>
        <xbrli:endDate>2022-04-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <span id="xdx_90B_edei--DocumentType_c20220414__20220414_zhk1Mkypvnvb"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):
<span id="xdx_908_edei--DocumentPeriodEndDate_c20220414__20220414_zJe1kYjXwtdg"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">April 14, 2022</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_90B_edei--EntityRegistrantName_c20220414__20220414_zEV7CsgW1Dk9"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" name="dei:EntityRegistrantName">NEKTAR THERAPEUTICS</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact Name of Registrant as Specified in Charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20220414__20220414_zd1EL53yE433"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityFileNumber_c20220414__20220414_zFP1S1HW888d"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" name="dei:EntityFileNumber">0-24006</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20220414__20220414_zBJgSWA13kG2"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" name="dei:EntityTaxIdentificationNumber">94-3134940</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State or Other Jurisdiction <br />
of Incorporation)</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission File Number)</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS Employer<br />
Identification No.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20220414__20220414_zDXbJEPMG5V6"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" name="dei:EntityAddressAddressLine1">455 Mission Bay Boulevard South</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityAddressCityOrTown_c20220414__20220414_zydLUPgc5zgd"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" name="dei:EntityAddressCityOrTown">San Francisco</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20220414__20220414_zfGzcGjB4A29"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20220414__20220414_zALacCJ0QUQc"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" name="dei:EntityAddressPostalZipCode">94158</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of Principal Executive Offices and
Zip Code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: (<span id="xdx_90E_edei--CityAreaCode_c20220414__20220414_zsqhDoEsUbQ6"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" name="dei:CityAreaCode">415</ix:nonNumeric></span>) <span id="xdx_903_edei--LocalPhoneNumber_c20220414__20220414_zvS0Dj0aCP9d"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" name="dei:LocalPhoneNumber">482-5300</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt 0pt 0; text-align: left">Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--WrittenCommunications_c20220414__20220414_zEAIU1FOkdxg"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--SolicitingMaterial_c20220414__20220414_zASOGmeAGsC9"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--PreCommencementTenderOffer_c20220414__20220414_zgtx1Ky8OOm8"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--PreCommencementIssuerTenderOffer_c20220414__20220414_zMutc4PflAye"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>Securities registered pursuant to Section 12(b) of the
Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading symbol(s)</b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--Security12bTitle_c20220414__20220414_zEbaZ5d8qPNe"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" name="dei:Security12bTitle">Common Stock, $0.0001 par value</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--TradingSymbol_c20220414__20220414_zbDXjjQQpbB8"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" name="dei:TradingSymbol">NKTR</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--SecurityExchangeName_c20220414__20220414_zKpPwXBqL4jk"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Global Select Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt 0pt 0; text-align: justify">Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span id="xdx_903_edei--EntityEmergingGrowthCompany_c20220414__20220414_zXRLKr8Jf0bj"><ix:nonNumeric contextRef="From2022-04-14to2022-04-14" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt 0pt 0; text-align: left">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 14, 2022, Nektar Therapeutics (&#8220;Nektar&#8221;)
and Bristol-Myers Squibb Company (&#8220;BMS&#8221;) announced results from the pre-planned analyses of the Phase 3 PIVOT-09 clinical
trial (the &#8220;PIVOT-09 Trial&#8221;) evaluating bempegaldesleukin (&#8220;BEMPEG&#8221;) in combination with Opdivo (nivolumab) in
patients with previously untreated advanced or metastatic renal cell carcinoma (&#8220;RCC&#8221;) and the Phase 2 PIVOT-10 clinical trial
(the &#8220;PIVOT-10 Trial&#8221;) evaluating BEMPEG in combination with Opdivo in patients with cisplatin-ineligible, locally advanced
or metastatic urothelial cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the PIVOT-09 Trial, Nektar and BMS were informed
by an independent Data Monitoring Committee (&#8220;DMC&#8221;) that a final analysis of objective response rate (&#8220;ORR&#8221;) as
assessed by Blinded Independent Central Review (&#8220;BICR&#8221;) showed that BEMPEG in combination with Opdivo did not meet the prespecified
boundary for statistical significance in comparison to the tyrosine kinase inhibitor (&#8220;TKI&#8221;) control arm in the International
Metastatic Renal Cell Carcinoma Database Consortium intermediate/poor-risk or all-risk populations. An interim analysis of overall survival
(&#8220;OS&#8221;) also did not meet the prespecified boundary for statistical significance in either of these populations. Given that
there was no clinical benefit in the doublet therapy arm compared to the TKI arm, the companies have decided to unblind the trial and
to perform no additional analyses for the OS endpoint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In the separate PIVOT-10 Trial, a final ORR analysis
assessed by BICR showed that BEMPEG in combination with Opdivo did not reach an efficacy threshold to support continuing the program in
urothelial carcinoma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on results from these studies, Nektar and
BMS have jointly decided to end the global clinical development program for BEMPEG in combination with Opdivo. In addition to these studies,
all other studies of BEMPEG in combination with Opdivo, including a pivotal study in muscle-invasive bladder cancer (CA045-009), a Phase
1/2 study of the doublet therapy in combination with TKI therapy in 1L RCC (CA045-011) and a Phase 1/2 study in recurrent and/or refractory
pediatric tumors (CA045-020), will be discontinued, allowing patients and their physicians to consider standard of care treatment options
for their specific conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A copy of the press release issued in connection
with the announcement is attached hereto as Exhibit 99.1, and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Further, in consultation with SFJ Pharmaceuticals
and based upon a recommendation from an independent DMC, Nektar has made the decision to discontinue its Phase 2/3 PROPEL-36 study of
BEMPEG in combination with Keytruda (pembrolizumab) in patients with metastatic or unresectable recurrent squamous cell carcinoma of the
head and neck. In addition, Nektar has also decided to discontinue its Phase 1/2 PROPEL study of BEMPEG in combination with Keytruda in
locally advanced or metastatic solid tumors, including non-small cell lung cancer. For all discontinued studies, Nektar will evaluate
its options in order to determine the most efficient plan for the responsible wind-down of the clinical program for BEMPEG.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to the release of its financial results for
the first quarter of 2022, Nektar expects to announce a new strategic plan to meet the cash runway goal that was discussed during Nektar&#8217;s
call with investors on March 14, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No</b>.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description&#160;</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea158456ex99-1_nektarther.htm">Press release titled &#8220;Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab).&#8221;</a></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 110.1pt; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEKTAR THERAPEUTICS</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 14, 2022 </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mark A. Wilson</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark A. Wilson</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General Counsel and Secretary</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVEKwjAQRE/QOyz5ltrECtJPi4pYRYqIv8GuEmyzZROrHslbGlvEZWFZZt6MECOxoqWpkeE0Lws4YNPW2iOUeEFGe8bgyNebDMIt8WqcZ219//7AnAKDgZnGcqKD0Fs747DKIEnHMh0rBVJl6Qz2WxF99ZzsxVRovdE1aFvBnqllg17za0g46CdZal591RHZGbIZyDgZ5DeoRCrYUacfxDcHRZGLaNRPJFZM9/Zbc3eeGljU2IQuN6D/jT4ZZUlM -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea158456ex99-1_nektarther.htm
<DESCRIPTION>PRESS RELEASE TITLED "NEKTAR AND BRISTOL MYERS SQUIBB ANNOUNCE UPDATE ON CLINICAL DEVELOPMENT PROGRAM FOR BEMPEGALDESLEUKIN (BEMPEG) IN COMBINATION WITH OPDIVO (NIVOLUMAB)."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;<IMG SRC="ex99-1_001.jpg" ALT=""></TD>
  <TD STYLE="text-align: right; width: 50%">&nbsp;<IMG SRC="ex99-1_002.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Nektar and Bristol Myers Squibb Announce Update
on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with <I>Opdivo</I> (nivolumab)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(PRINCETON, N.J., &amp; SAN FRANCISCO, April 14,
2022) -- Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb (NYSE: BMY) today announced that based on results from pre-planned
analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with <I>Opdivo</I> (nivolumab) in renal cell
carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the global clinical development program for bempegaldesleukin
in combination with <I>Opdivo</I>. These studies and all other ongoing studies in the program will be discontinued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the Phase 3 PIVOT-09 study in patients
with previously untreated advanced or metastatic RCC, Nektar and Bristol Myers Squibb were informed by an independent Data
Monitoring Committee (DMC) that a final analysis of objective response rate (ORR) as assessed by Blinded Independent Central Review
(BICR) showed that bempegaldesleukin in combination with <I>Opdivo</I> did not meet the prespecified boundary for statistical
significance in comparison to the tyrosine kinase inhibitor (TKI) control arm in the International Metastatic Renal Cell Carcinoma
Database Consortium (IMDC) intermediate/poor-risk or all-risk populations. An interim analysis of overall survival (OS) also did not
meet the prespecified boundary for statistical significance in either of these populations. Given there was no clinical benefit in
the doublet therapy arm compared to the TKI arm, the companies have decided to unblind the trial and to perform no additional
analyses for the OS endpoint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the separate Phase 2 PIVOT-10 study of the bempegaldesleukin/<I>Opdivo</I>
doublet in patients with cisplatin-ineligible, locally advanced or metastatic urothelial cancer, a final ORR analysis assessed by BICR
showed that bempegaldesleukin in combination with <I>Opdivo</I> did not reach an efficacy threshold to support continuing the program
in urothelial carcinoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The companies will review the data for both studies
and plan to share the results with the scientific community.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">All other
studies of </FONT>bempegaldesleukin <FONT STYLE="background-color: white">in combination with <I>Opdivo</I>, including a pivotal study
in muscle-invasive bladder cancer (CA045-009), a Phase 1/2 study of the doublet in combination with TKI therapy in 1L RCC (CA045-011)
and a Phase 1/2 study in recurrent and/or refractory pediatric tumors (CA045-020), will be discontinued, allowing patients and their physicians
to consider standard of care treatment options for their specific conditions</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;As a leader in developing innovative therapies
for patients with cancer, we are committed to continuing to explore novel combinations and pathways and advancing research that may help
cancer patients achieve better outcomes,&rdquo; said Jonathan Cheng, senior vice president and head of oncology development, Bristol Myers
Squibb. &ldquo;We are immensely grateful to the patients and investigators who participated in these studies.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The companies previously announced in March that
two pivotal studies in melanoma would be discontinued based on results in the Phase 3 PIVOT IO-001 study in metastatic melanoma. Over
the coming months, the companies will work jointly to discontinue the clinical program for bempegaldesleukin <FONT STYLE="background-color: white">in
combination with <I>Opdivo</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;We thank BMS for their collaboration on
the studies of bempegaldesleukin. Nektar remains dedicated to the development of therapeutics to treat cancer and auto-immune disease,&rdquo;
said Jonathan Zalevsky, chief research and development officer of Nektar Therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About PIVOT-09</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">PIVOT-09 is a global, randomized Phase 3 study
evaluating bempegaldesleukin combined with <I>Opdivo</I> versus investigator&rsquo;s choice of a tyrosine kinase inhibitor (TKI) therapy (either
sunitinib or cabozantinib) in patients with previously untreated advanced renal cell carcinoma in the IMDC all-risk and the IMDC intermediate-
or poor-risk categories. A total of 623 patients were randomized 1:1 to receive a combination of bempegaldesleukin 0.006 mg/kg and <I>Opdivo</I>
360 mg every three weeks in an outpatient setting by intravenous infusion or a specified dose of TKI therapy. Patients were treated until
disease recurrence, unacceptable toxicity or withdrawal of consent for up to 24 months. The study is sponsored and conducted by Nektar
Therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About PIVOT-10</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">PIVOT-10 is a global Phase 2 single-arm study
evaluating bempegaldesleukin combined with <I>Opdivo</I> in patients deemed ineligible for cisplatin therapy including those whose
baseline tumor cells express low levels of PD-L1. A total of 192 patients were enrolled and patients were treated until disease
recurrence, unacceptable toxicity or withdrawal of consent for up to 24 months. The study is sponsored and conducted by Nektar
Therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About Renal Cell Carcinoma</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Renal cell carcinoma (RCC) is the most common type
of kidney cancer in adults, accounting for more than 431,000 new cases and 179,000 deaths worldwide each year. RCC is approximately twice
as common in men as in women, with the highest rates of the disease in North America and Europe. The five-year survival rate for those
diagnosed with metastatic, or advanced, kidney cancer is 13.9%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About Urothelial Carcinoma</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Bladder cancer is the 10th most common cancer in
the world, with more than 573,000 new cases diagnosed annually. Urothelial carcinoma, which most frequently begins in the cells that line
the inside of the bladder, accounts for approximately 90% of bladder cancer cases. In addition to the bladder, urothelial carcinoma can
occur in other parts of the urinary tract, including the ureters and renal pelvis. The majority of urothelial carcinomas are diagnosed
at an early stage, but rates of recurrence are high. Approximately 50% of patients who undergo surgery for muscle-invasive disease will
experience disease recurrence. Additionally, approximately 20% to 25% of patients with urothelial carcinoma develop metastatic disease.
For patients with metastatic cancer, the prognosis is poor, with a median overall survival of approximately 12 to 14 months when treated
with systemic therapy. The poor durability of responses in the first-line setting presents a major challenge in the treatment of metastatic
disease, and there are limited treatment options in the second-line setting for patients with advanced urothelial carcinoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Bristol Myers Squibb: Creating a Better Future for People with
Cancer</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Bristol Myers Squibb is inspired by a single vision
&mdash; transforming patients&rsquo; lives through science. The goal of the company&rsquo;s cancer research is to deliver medicines that
offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that
have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine, and
through innovative digital platforms, are turning data into insights that sharpen their focus. Deep scientific expertise, cutting-edge
capabilities and discovery platforms enable the company to look at cancer from every angle. Cancer can have a relentless grasp on many
parts of a patient&rsquo;s life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis
to survivorship. Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better
future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About <I>Opdivo</I></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Opdivo</I>&nbsp;is a programmed death-1 (PD-1)
immune checkpoint inhibitor that is designed to uniquely harness the body&rsquo;s own immune system to help restore anti-tumor immune
response. By harnessing the body&rsquo;s own immune system to fight cancer,&nbsp;<I>Opdivo</I>&nbsp;has become an important treatment
option across multiple cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Opdivo</I>&rsquo;s leading global development
program is based on Bristol Myers Squibb&rsquo;s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical
trials across all phases, including Phase 3, in a variety of tumor types. To date, the&nbsp;<I>Opdivo</I>&nbsp;clinical development program
has treated more than 35,000 patients. The&nbsp;<I>Opdivo</I>&nbsp;trials have contributed to gaining a deeper understanding of the potential
role of biomarkers in patient care, particularly regarding how patients may benefit from&nbsp;<I>Opdivo</I>&nbsp;across the continuum
of PD-L1 expression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In July 2014,&nbsp;<I>Opdivo</I>&nbsp;was the first
PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world.&nbsp;<I>Opdivo</I>&nbsp;is currently approved in
more than 65 countries, including the United States, the European Union, Japan and China. In October 2015, the Company&rsquo;s <I>Opdivo</I>
and <I>Yervoy </I>combination regimen was the first Immuno-Oncology to receive regulatory approval for the treatment of metastatic melanoma
and is currently approved in more than 50 countries, including the United States and the European Union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>INDICATIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), as a single agent, is indicated
for the treatment of adult patients with unresectable or metastatic melanoma.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with YERVOY<SUP>&reg;</SUP>
(ipilimumab), is indicated for the treatment of adult patients with unresectable or metastatic melanoma.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab) is indicated for the adjuvant treatment
of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with platinum-doublet
chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors &ge;4 cm or node positive) non-small cell
lung cancer (NSCLC).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with YERVOY<SUP>&reg;</SUP>
(ipilimumab), is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors
express PD-L1 (&ge;1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with YERVOY<SUP>&reg;</SUP>
(ipilimumab) and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic
or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab) is indicated for the treatment of
adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with
EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving
OPDIVO.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with YERVOY<SUP>&reg;</SUP>
(ipilimumab), is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with YERVOY<SUP>&reg;</SUP>
(ipilimumab), is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma
(RCC).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with cabozantinib,
is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab) is indicated for the treatment of
adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab) is indicated for the treatment of
adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation
(HSCT) and brentuximab vedotin or after 3 or more lines of systemic therapy that includes autologous HSCT. This indication is approved
under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification
and description of clinical benefit in confirmatory trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab) is indicated for the treatment of
adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after
platinum-based therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab) is indicated for the treatment of
adult patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing
chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), as a single agent, is indicated
for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical
resection of UC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), as a single agent, is indicated
for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair
deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and
irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued
approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with YERVOY<SUP>&reg;</SUP>
(ipilimumab), is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high
(MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine,
oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with YERVOY<SUP>&reg;</SUP>
(ipilimumab), is indicated for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with
sorafenib. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval
for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab) is indicated for the treatment of
adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine-
and platinum-based chemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab) is indicated for the adjuvant treatment
of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received
neoadjuvant chemoradiotherapy (CRT).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with fluoropyrimidine-
and platinum- containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal
junction cancer, and esophageal adenocarcinoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>IMPORTANT SAFETY INFORMATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Severe and Fatal Immune-Mediated Adverse Reactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Immune-mediated adverse reactions listed herein may not include all
possible severe and fatal immune-mediated adverse reactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Immune-mediated adverse reactions, which may be severe or fatal, can
occur in any organ system or tissue. While immune-mediated adverse reactions usually manifest during treatment, they can also occur after
discontinuation of OPDIVO or YERVOY. Early identification and management are essential to ensure safe use of OPDIVO and YERVOY. Monitor
for signs and symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate clinical chemistries
including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and periodically during
treatment with OPDIVO and before each dose of YERVOY. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup
to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Withhold or permanently discontinue OPDIVO and YERVOY depending on
severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). In general, if OPDIVO or YERVOY
interruption or discontinuation is required, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until
improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least
1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled
with corticosteroid therapy. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g.,
endocrinopathies and dermatologic reactions) are discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Immune-Mediated Pneumonitis</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO and YERVOY can cause immune-mediated pneumonitis. The incidence
of pneumonitis is higher in patients who have received prior thoracic radiation. In patients receiving OPDIVO monotherapy, immune- mediated
pneumonitis occurred in 3.1% (61/1994) of patients, including Grade 4 (&lt;0.1%), Grade 3 (0.9%), and Grade 2 (2.1%). In patients receiving
OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune-mediated pneumonitis occurred in 7% (31/456) of patients, including Grade 4 (0.2%),
Grade 3 (2.0%), and Grade 2 (4.4%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated pneumonitis
occurred in 3.9% (26/666) of patients, including Grade 3 (1.4%) and Grade 2 (2.6%). In NSCLC patients receiving OPDIVO 3 mg/kg every 2
weeks with YERVOY 1 mg/kg every 6 weeks, immune-mediated pneumonitis occurred in 9% (50/576) of patients, including Grade 4 (0.5%), Grade
3 (3.5%), and Grade 2 (4.0%). Four patients (0.7%) died due to pneumonitis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In Checkmate 205 and 039, pneumonitis, including interstitial lung
disease, occurred in 6.0% (16/266) of patients receiving OPDIVO. Immune-mediated pneumonitis occurred in 4.9% (13/266) of patients receiving
OPDIVO, including Grade 3 (n=1) and Grade 2 (n=12).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Immune-Mediated Colitis</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO and YERVOY can cause immune-mediated colitis, which may be fatal.
A common symptom included in the definition of colitis was diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in
patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious
workup to exclude alternative etiologies. In patients receiving OPDIVO monotherapy, immune-mediated colitis occurred in 2.9% (58/1994)
of patients, including Grade 3 (1.7%) and Grade 2 (1%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune-mediated
colitis occurred in 25% (115/456) of patients, including Grade 4 (0.4%), Grade 3 (14%) and Grade 2 (8%). In patients receiving OPDIVO
3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated colitis occurred in 9% (60/666) of patients, including Grade 3 (4.4%) and Grade
2 (3.7%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Immune-Mediated Hepatitis and Hepatotoxicity</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO and YERVOY can cause immune-mediated hepatitis. In patients
receiving OPDIVO monotherapy, immune-mediated hepatitis occurred in 1.8% (35/1994) of patients, including Grade 4 (0.2%), Grade 3 (1.3%),
and Grade 2 (0.4%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune- mediated hepatitis occurred in 15%
(70/456) of patients, including Grade 4 (2.4%), Grade 3 (11%), and Grade 2 (1.8%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1
mg/kg every 3 weeks, immune-mediated hepatitis occurred in 7% (48/666) of patients, including Grade 4 (1.2%), Grade 3 (4.9%), and Grade
2 (0.4%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO in combination with cabozantinib can cause hepatic toxicity
with higher frequencies of Grade 3 and 4 ALT and AST elevations compared to OPDIVO alone. Consider more frequent monitoring of liver enzymes
as compared to when the drugs are administered as single agents. In patients receiving OPDIVO and cabozantinib, Grades 3 and 4 increased
ALT or AST were seen in 11% of patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Immune-Mediated Endocrinopathies</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO and YERVOY can cause primary or secondary adrenal insufficiency,
immune-mediated hypophysitis, immune-mediated thyroid disorders, and Type 1 diabetes mellitus, which can present with diabetic ketoacidosis.
Withhold OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing
Information). For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically
indicated. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects.
Hypophysitis can cause hypopituitarism; initiate hormone replacement as clinically indicated. Thyroiditis can present with or without
endocrinopathy. Hypothyroidism can follow hyperthyroidism; initiate hormone replacement or medical management as clinically indicated.
Monitor patients for hyperglycemia or other signs and symptoms of diabetes; initiate treatment with insulin as clinically indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In patients receiving OPDIVO monotherapy, adrenal insufficiency occurred
in 1% (20/1994), including Grade 3 (0.4%) and Grade 2 (0.6%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks,
adrenal insufficiency occurred in 8% (35/456), including Grade 4 (0.2%), Grade 3 (2.4%), and Grade 2 (4.2%). In patients receiving OPDIVO
3 mg/kg with YERVOY 1 mg/kg every 3 weeks, adrenal insufficiency occurred in 7% (48/666) of patients, including Grade 4 (0.3%), Grade
3 (2.5%), and Grade 2 (4.1%). In patients receiving OPDIVO and cabozantinib, adrenal insufficiency occurred in 4.7% (15/320) of patients,
including Grade 3 (2.2%) and Grade 2 (1.9%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, adrenal insufficiency
occurred in 8% (35/456), including Grade 4 (0.2%), Grade 3 (2.4%), and Grade 2 (4.2%). In patients receiving OPDIVO 3 mg/kg with YERVOY
1 mg/kg every 3 weeks, adrenal insufficiency occurred in 7% (48/666) of patients, including Grade 4 (0.3%), Grade 3 (2.5%), and Grade
2 (4.1%). In patients receiving OPDIVO and cabozantinib, adrenal insufficiency occurred in 4.7% (15/320) of patients, including Grade
3 (2.2%) and Grade 2 (1.9%).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In patients receiving OPDIVO monotherapy, hypophysitis occurred in
0.6% (12/1994) of patients, including Grade 3 (0.2%) and Grade 2 (0.3%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every
3 weeks, hypophysitis occurred in 9% (42/456), including Grade 3 (2.4%) and Grade 2 (6%). In patients receiving OPDIVO 3 mg/kg with YERVOY
1 mg/kg every 3 weeks, hypophysitis occurred in 4.4% (29/666) of patients, including Grade 4 (0.3%), Grade 3 (2.4%), and Grade 2 (0.9%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In patients receiving OPDIVO monotherapy, thyroiditis occurred in 0.6%
(12/1994) of patients, including Grade 2 (0.2%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, thyroiditis occurred
in 2.7% (22/666) of patients, including Grade 3 (4.5%) and Grade 2 (2.2%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In patients receiving OPDIVO monotherapy, hyperthyroidism occurred
in 2.7% (54/1994) of patients, including Grade 3 (&lt;0.1%) and Grade 2 (1.2%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg
every 3 weeks, hyperthyroidism occurred in 9% (42/456) of patients, including Grade 3 (0.9%) and Grade 2 (4.2%). In patients receiving
OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, hyperthyroidism occurred in 12% (80/666) of patients, including Grade 3 (0.6%) and Grade
2 (4.5%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In patients receiving OPDIVO monotherapy, hypothyroidism occurred in
8% (163/1994) of patients, including Grade 3 (0.2%) and Grade 2 (4.8%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every
3 weeks, hypothyroidism occurred in 20% (91/456) of patients, including Grade 3 (0.4%) and Grade 2 (11%). In patients receiving OPDIVO
3 mg/kg with YERVOY 1 mg/kg every 3 weeks, hypothyroidism occurred in 18% (122/666) of patients, including Grade 3 (0.6%) and Grade 2
(11%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In patients receiving OPDIVO monotherapy, diabetes occurred in 0.9%
(17/1994) of patients, including Grade 3 (0.4%) and Grade 2 (0.3%), and 2 cases of diabetic ketoacidosis. In patients receiving OPDIVO
3 mg/kg with YERVOY 1 mg/kg every 3 weeks, diabetes occurred in 2.7% (15/666) of patients, including Grade 4 (0.6%), Grade 3 (0.3%), and
Grade 2 (0.9%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Immune-Mediated Nephritis with Renal Dysfunction</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO and YERVOY can cause immune-mediated nephritis. In patients
receiving OPDIVO monotherapy, immune-mediated nephritis and renal dysfunction occurred in 1.2% (23/1994) of patients, including Grade
4 (&lt;0.1%), Grade 3 (0.5%), and Grade 2 (0.6%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated
nephritis with renal dysfunction occurred in 4.1% (27/666) of patients, including Grade 4 (0.6%), Grade 3 (1.1%), and Grade 2 (2.2%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Immune-Mediated Dermatologic Adverse Reactions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO can cause immune-mediated rash or dermatitis. Exfoliative dermatitis,
including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS)
has occurred with PD-1/PD-L1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate
nonexfoliative rashes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">YERVOY can cause immune-mediated rash or dermatitis, including bullous
and exfoliative dermatitis, SJS, TEN, and DRESS. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate
non- bullous/exfoliative rashes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Withhold or permanently discontinue OPDIVO and YERVOY depending on
severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In patients receiving OPDIVO monotherapy, immune-mediated rash occurred
in 9% (171/1994) of patients, including Grade 3 (1.1%) and Grade 2 (2.2%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every
3 weeks, immune-mediated rash occurred in 28% (127/456) of patients, including Grade 3 (4.8%) and Grade 2 (10%). In patients receiving
OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated rash occurred in 16% (108/666) of patients, including Grade 3 (3.5%)
and Grade 2 (4.2%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Other Immune-Mediated Adverse Reactions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following clinically significant immune-mediated adverse reactions
occurred at an incidence of &lt;1% (unless otherwise noted) in patients who received OPDIVO monotherapy or OPDIVO in combination with
YERVOY or were reported with the use of other PD-1/PD-L1 blocking antibodies. Severe or fatal cases have been reported for some of these
adverse reactions: <I>cardiac/vascular: </I>myocarditis, pericarditis, vasculitis; <I>nervous system: </I>meningitis, encephalitis, myelitis
and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barr&eacute; syndrome, nerve paresis, autoimmune
neuropathy; <I>ocular: </I>uveitis, iritis, and other ocular inflammatory toxicities can occur; <I>gastrointestinal: </I>pancreatitis
to include increases in serum amylase and lipase levels, gastritis, duodenitis; <I>musculoskeletal and connective tissue: </I>myositis/polymyositis,
rhabdomyolysis, and associated sequelae including renal failure, arthritis, polymyalgia rheumatica; <I>endocrine: </I>hypoparathyroidism;
<I>other (hematologic/immune): </I>hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis (HLH), systemic inflammatory
response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid
organ transplant rejection.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the immune-mediated adverse reactions listed above,
across clinical trials of YERVOY monotherapy or in combination with OPDIVO, the following clinically significant immune-mediated adverse
reactions, some with fatal outcome, occurred in &lt;1% of patients unless otherwise specified: <I>nervous system: </I>autoimmune neuropathy
(2%), myasthenic syndrome/myasthenia gravis, motor dysfunction; <I>cardiovascular: </I>angiopathy, temporal arteritis; <I>ocular: </I>blepharitis,
episcleritis, orbital myositis, scleritis; <I>gastrointestinal: </I>pancreatitis (1.3%); <I>other (hematologic/immune): </I>conjunctivitis,
cytopenias (2.5%), eosinophilia (2.1%), erythema multiforme, hypersensitivity vasculitis, neurosensory hypoacusis, psoriasis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some ocular IMAR cases can be associated with retinal detachment. Various
grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions,
consider a Vogt-Koyanagi-Harada&ndash;like syndrome, which has been observed in patients receiving OPDIVO and YERVOY, as this may require
treatment with systemic corticosteroids to reduce the risk of permanent vision loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Infusion-Related Reactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">OPDIVO and YERVOY can cause severe infusion-related reactions. Discontinue
OPDIVO and YERVOY in patients with severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Interrupt or slow the rate
of infusion in patients with mild (Grade 1) or moderate (Grade 2) infusion-related reactions. In patients receiving OPDIVO monotherapy
as a 60-minute infusion, infusion-related reactions occurred in 6.4% (127/1994) of patients. In a separate trial in which patients received
OPDIVO monotherapy as a 60-minute infusion or a 30- minute infusion, infusion-related reactions occurred in 2.2% (8/368) and 2.7% (10/369)
of patients, respectively. Additionally, 0.5% (2/368) and 1.4% (5/369) of patients, respectively, experienced adverse reactions within
48 hours of infusion that led to dose delay, permanent discontinuation or withholding of OPDIVO. In melanoma patients receiving OPDIVO
1 mg/kg with YERVOY 3 mg/kg every 3 weeks, infusion-related reactions occurred in 2.5% (10/407) of patients. In HCC patients receiving
OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, infusion-related reactions occurred in 8% (4/49) of patients. In RCC patients receiving
OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, infusion-related reactions occurred in 5.1% (28/547) of patients. In MSI- H/dMMR mCRC
patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, infusion-related reactions occurred in 4.2% (5/119) of patients.
In MPM patients receiving OPDIVO 3 mg/kg every 2 weeks with YERVOY 1 mg/kg every 6 weeks, infusion-related reactions occurred in 12% (37/300)
of patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Complications of Allogeneic Hematopoietic Stem Cell Transplantation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Fatal and other serious complications can occur in patients who receive
allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with OPDIVO or YERVOY. Transplant-related complications
include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity
conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening
therapy between OPDIVO or YERVOY and allogeneic HSCT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Follow patients closely for evidence of transplant-related complications
and intervene promptly. Consider the benefit versus risks of treatment with OPDIVO and YERVOY prior to or after an allogeneic HSCT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Embryo-Fetal Toxicity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on its mechanism of action and findings from animal studies,
OPDIVO and YERVOY can cause fetal harm when administered to a pregnant woman. The effects of YERVOY are likely to be greater during the
second and third trimesters of pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential
to use effective contraception during treatment with OPDIVO and YERVOY and for at least 5 months after the last dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Increased Mortality in Patients with Multiple Myeloma when OPDIVO
is Added to a Thalidomide Analogue and Dexamethasone</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In randomized clinical trials in patients with multiple myeloma, the
addition of OPDIVO to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of patients with multiple myeloma
with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled
clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lactation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no data on the presence of OPDIVO or YERVOY in human milk,
the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in breastfed
children, advise women not to breastfeed during treatment and for 5 months after the last dose.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Serious Adverse Reactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In Checkmate 037, serious adverse reactions occurred in 41% of patients
receiving OPDIVO (n=268). Grade 3 and 4 adverse reactions occurred in 42% of patients receiving OPDIVO. The most frequent Grade 3 and
4 adverse drug reactions reported in 2% to &lt;5% of patients receiving OPDIVO were abdominal pain, hyponatremia, increased aspartate
aminotransferase, and increased lipase. In Checkmate 066, serious adverse reactions occurred in 36% of patients receiving OPDIVO (n=206).
Grade 3 and 4 adverse reactions occurred in 41% of patients receiving OPDIVO. The most frequent Grade 3 and 4 adverse reactions reported
in &ge;2% of patients receiving OPDIVO were gamma-glutamyltransferase increase (3.9%) and diarrhea (3.4%). In Checkmate 067, serious adverse
reactions (74% and 44%), adverse reactions leading to permanent discontinuation (47% and 18%) or to dosing delays (58% and 36%), and Grade
3 or 4 adverse reactions (72% and 51%) all occurred more frequently in the OPDIVO plus YERVOY arm (n=313) relative to the OPDIVO arm (n=313).
The most frequent (&ge;10%) serious adverse reactions in the OPDIVO plus YERVOY arm and the OPDIVO arm, respectively, were diarrhea (13%
and 2.2%), colitis (10% and 1.9%), and pyrexia (10% and 1.0%). In Checkmate 238, serious adverse reactions occurred in 18% of patients
receiving OPDIVO (n=452). Grade 3 or 4 adverse reactions occurred in 25% of OPDIVO-treated patients (n=452). The most frequent Grade 3
and 4 adverse reactions reported in &ge;2% of OPDIVO-treated patients were diarrhea and increased lipase and amylase. In Checkmate 816,
serious adverse reactions occurred in 30% of patients (n=176) who were treated with OPDIVO in combination with platinum-doublet chemotherapy.
Serious adverse reactions in &gt;2% included pneumonia and vomiting. No fatal adverse reactions occurred in patients who received OPDIVO
in combination with platinum-doublet chemotherapy. In Checkmate 227, serious adverse reactions occurred in 58% of patients (n=576). The
most frequent (&ge;2%) serious adverse reactions were pneumonia, diarrhea/colitis, pneumonitis, hepatitis, pulmonary embolism, adrenal
insufficiency, and hypophysitis. Fatal adverse reactions occurred in 1.7% of patients; these included events of pneumonitis (4 patients),
myocarditis, acute kidney injury, shock, hyperglycemia, multi-system organ failure, and renal failure. In Checkmate 9LA, serious adverse
reactions occurred in 57% of patients (n=358). The most frequent (&gt;2%) serious adverse reactions were pneumonia, diarrhea, febrile
neutropenia, anemia, acute kidney injury, musculoskeletal pain, dyspnea, pneumonitis, and respiratory failure. Fatal adverse reactions
occurred in 7 (2%) patients, and included hepatic toxicity, acute renal failure, sepsis, pneumonitis, diarrhea with hypokalemia, and massive
hemoptysis in the setting of thrombocytopenia. In Checkmate 017 and 057, serious adverse reactions occurred in 46% of patients receiving
OPDIVO (n=418). The most frequent serious adverse reactions reported in &ge;2% of patients receiving OPDIVO were pneumonia, pulmonary
embolism, dyspnea, pyrexia, pleural effusion, pneumonitis, and respiratory failure. In Checkmate 057, fatal adverse reactions occurred;
these included events of infection (7 patients, including one case of <I>Pneumocystis jirovecii </I>pneumonia), pulmonary embolism (4
patients), and limbic encephalitis (1 patient). In Checkmate 743, serious adverse reactions occurred in 54% of patients receiving OPDIVO
plus YERVOY. The most frequent serious adverse reactions reported in &ge;2% of patients were pneumonia, pyrexia, diarrhea, pneumonitis,
pleural effusion, dyspnea, acute kidney injury, infusion-related reaction, musculoskeletal pain, and pulmonary embolism. Fatal adverse
reactions occurred in 4 (1.3%) patients and included pneumonitis, acute heart failure, sepsis, and encephalitis. In Checkmate 214, serious
adverse reactions occurred in 59% of patients receiving OPDIVO plus YERVOY (n=547). The most frequent serious adverse reactions reported
in &ge;2% of patients were diarrhea, pyrexia, pneumonia, pneumonitis, hypophysitis, acute kidney injury, dyspnea, adrenal insufficiency,
and colitis. In Checkmate 9ER, serious adverse reactions occurred in 48% of patients receiving OPDIVO and cabozantinib (n=320). The most
frequent serious adverse reactions reported in &ge;2% of patients were diarrhea, pneumonia, pneumonitis, pulmonary embolism, urinary tract
infection, and hyponatremia. Fatal intestinal perforations occurred in 3 (0.9%) patients. In Checkmate 025, serious adverse reactions
occurred in 47% of patients receiving OPDIVO (n=406). The most frequent serious adverse reactions reported in &ge;2% of patients were
acute kidney injury, pleural effusion, pneumonia, diarrhea, and hypercalcemia. In Checkmate 205 and 039, adverse reactions leading to
discontinuation occurred in 7% and dose delays due to adverse reactions occurred in 34% of patients (n=266). Serious adverse reactions
occurred in 26% of patients. The most frequent serious adverse reactions reported in &ge;1% of patients were pneumonia, infusion-related
reaction, pyrexia, colitis or diarrhea, pleural effusion, pneumonitis, and rash. Eleven patients died from causes other than disease progression:
3 from adverse reactions within 30 days of the last OPDIVO dose, 2 from infection 8 to 9 months after completing OPDIVO, and 6 from complications
of allogeneic HSCT. In Checkmate 141, serious adverse reactions occurred in 49% of patients receiving OPDIVO (n=236). The most frequent
serious adverse reactions reported in &ge;2% of patients receiving OPDIVO were pneumonia, dyspnea, respiratory failure, respiratory tract
infection, and sepsis. In Checkmate 275, serious adverse reactions occurred in 54% of patients receiving OPDIVO (n=270). The most frequent
serious adverse reactions reported in &ge;2% of patients receiving OPDIVO were urinary tract infection, sepsis, diarrhea, small intestine
obstruction, and general physical health deterioration. In Checkmate 274, serious adverse reactions occurred in 30% of patients receiving
OPDIVO (n=351). The most frequent serious adverse reaction reported in &ge;2% of patients receiving OPDIVO was urinary tract infection.
Fatal adverse reactions occurred in 1% of patients; these included events of pneumonitis (0.6%). In Checkmate 142 in MSI-H/dMMR mCRC patients
receiving OPDIVO with YERVOY (n=119), serious adverse reactions occurred in 47% of patients. The most frequent serious adverse reactions
reported in &ge;2% of patients were colitis/diarrhea, hepatic events, abdominal pain, acute kidney injury, pyrexia, and dehydration. In
Checkmate 040, serious adverse reactions occurred in 59% of patients receiving OPDIVO with YERVOY (n=49). Serious adverse reactions reported
in &ge;4% of patients were pyrexia, diarrhea, anemia, increased AST, adrenal insufficiency, ascites, esophageal varices hemorrhage, hyponatremia,
increased blood bilirubin, and pneumonitis. In Attraction-3, serious adverse reactions occurred in 38% of patients receiving OPDIVO (n=209).
Serious adverse reactions reported in &ge;2% of patients who received OPDIVO were pneumonia, esophageal fistula, interstitial lung disease,
and pyrexia. The following fatal adverse reactions occurred in patients who received OPDIVO: interstitial lung disease or pneumonitis
(1.4%), pneumonia (1.0%), septic shock (0.5%), esophageal fistula (0.5%), gastrointestinal hemorrhage (0.5%), pulmonary embolism (0.5%),
and sudden death (0.5%). In Checkmate 577, serious adverse reactions occurred in 33% of patients receiving OPDIVO (n=532). A serious adverse
reaction reported in &ge;2% of patients who received OPDIVO was pneumonitis. A fatal reaction of myocardial infarction occurred in one
patient who received OPDIVO. In Checkmate 649, serious adverse reactions occurred in 52% of patients treated with OPDIVO in combination
with chemotherapy (n=782). The most frequent serious adverse reactions reported in &ge;2% of patients treated with OPDIVO in combination
with chemotherapy were vomiting (3.7%), pneumonia (3.6%), anemia (3.6%), pyrexia (2.8%), diarrhea (2.7%), febrile neutropenia (2.6%),
and pneumonitis (2.4%). Fatal adverse reactions occurred in 16 (2.0%) patients who were treated with OPDIVO in combination with chemotherapy;
these included pneumonitis (4 patients), febrile neutropenia (2 patients), stroke (2 patients), gastrointestinal toxicity, intestinal
mucositis, septic shock, pneumonia, infection, gastrointestinal bleeding, mesenteric vessel thrombosis, and disseminated intravascular
coagulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Adverse Reactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In Checkmate 037, the most common adverse reaction (&ge;20%) reported
with OPDIVO (n=268) was rash (21%). In Checkmate 066, the most common adverse reactions (&ge;20%) reported with OPDIVO (n=206) vs dacarbazine
(n=205) were fatigue (49% vs 39%), musculoskeletal pain (32% vs 25%), rash (28% vs 12%), and pruritus (23% vs 12%). In Checkmate 067,
the most common (&ge;20%) adverse reactions in the OPDIVO plus YERVOY arm (n=313) were fatigue (62%), diarrhea (54%), rash (53%), nausea
(44%), pyrexia (40%), pruritus (39%), musculoskeletal pain (32%), vomiting (31%), decreased appetite (29%), cough (27%), headache (26%),
dyspnea (24%), upper respiratory tract infection (23%), arthralgia (21%), and increased transaminases (25%). In Checkmate 067, the most
common (&ge;20%) adverse reactions in the OPDIVO arm (n=313) were fatigue (59%), rash (40%), musculoskeletal pain (42%), diarrhea (36%),
nausea (30%), cough (28%), pruritus (27%), upper respiratory tract infection (22%), decreased appetite (22%), headache (22%), constipation
(21%), arthralgia (21%), and vomiting (20%). In Checkmate 238, the most common adverse reactions (&ge;20%) reported in OPDIVO- treated
patients (n=452) vs ipilimumab-treated patients (n=453) were fatigue (57% vs 55%), diarrhea (37% vs 55%), rash (35% vs 47%), musculoskeletal
pain (32% vs 27%), pruritus (28% vs 37%), headache (23% vs 31%), nausea (23% vs 28%), upper respiratory infection (22% vs 15%), and abdominal
pain (21% vs 23%). The most common immune-mediated adverse reactions were rash (16%), diarrhea/colitis (6%), and hepatitis (3%). In Checkmate
816, the most common (&gt;20%) adverse reactions in the OPDIVO plus chemotherapy arm (n=176) were nausea (38%), constipation (34%), fatigue
(26%), decreased appetite (20%), and rash (20%). In Checkmate 227, the most common (&ge;20%) adverse reactions were fatigue (44%), rash
(34%), decreased appetite (31%), musculoskeletal pain (27%), diarrhea/colitis (26%), dyspnea (26%), cough (23%), hepatitis (21%), nausea
(21%), and pruritus (21%). In Checkmate 9LA, the most common (&gt;20%) adverse reactions were fatigue (49%), musculoskeletal pain (39%),
nausea (32%), diarrhea (31%), rash (30%), decreased appetite (28%), constipation (21%), and pruritus (21%). In Checkmate 017 and 057,
the most common adverse reactions (&ge;20%) in patients receiving OPDIVO (n=418) were fatigue, musculoskeletal pain, cough, dyspnea, and
decreased appetite. In Checkmate 743, the most common adverse reactions (&ge;20%) in patients receiving OPDIVO plus YERVOY were fatigue
(43%), musculoskeletal pain (38%), rash (34%), diarrhea (32%), dyspnea (27%), nausea (24%), decreased appetite (24%), cough (23%), and
pruritus (21%). In Checkmate 214, the most common adverse reactions (&ge;20%) reported in patients treated with OPDIVO plus YERVOY (n=547)
were fatigue (58%), rash (39%), diarrhea (38%), musculoskeletal pain (37%), pruritus (33%), nausea (30%), cough (28%), pyrexia (25%),
arthralgia (23%), decreased appetite (21%), dyspnea (20%), and vomiting (20%). In Checkmate 9ER, the most common adverse reactions (&ge;20%)
in patients receiving OPDIVO and cabozantinib (n=320) were diarrhea (64%), fatigue (51%), hepatotoxicity (44%), palmar-plantar erythrodysaesthesia
syndrome (40%), stomatitis (37%), rash (36%), hypertension (36%), hypothyroidism (34%), musculoskeletal pain (33%), decreased appetite
(28%), nausea (27%), dysgeusia (24%), abdominal pain (22%), cough (20%) and upper respiratory tract infection (20%). In Checkmate 025,
the most common adverse reactions (&ge;20%) reported in patients receiving OPDIVO (n=406) vs everolimus (n=397) were fatigue (56% vs 57%),
cough (34% vs 38%), nausea (28% vs 29%), rash (28% vs 36%), dyspnea (27% vs 31%), diarrhea (25% vs 32%), constipation (23% vs 18%), decreased
appetite (23% vs 30%), back pain (21% vs 16%), and arthralgia (20% vs 14%). In Checkmate 205 and 039, the most common adverse reactions
(&ge;20%) reported in patients receiving OPDIVO (n=266) were upper respiratory tract infection (44%), fatigue (39%), cough (36%), diarrhea
(33%), pyrexia (29%), musculoskeletal pain (26%), rash (24%), nausea (20%) and pruritus (20%). In Checkmate 141, the most common adverse
reactions (&ge;10%) in patients receiving OPDIVO (n=236) were cough (14%) and dyspnea (14%) at a higher incidence than investigator&rsquo;s
choice. In Checkmate 275, the most common adverse reactions (&ge;20%) reported in patients receiving OPDIVO (n=270) were fatigue (46%),
musculoskeletal pain (30%), nausea (22%), and decreased appetite (22%). In Checkmate 274, the most common adverse reactions (&ge;20%)
reported in patients receiving OPDIVO (n=351) were rash (36%), fatigue (36%), diarrhea (30%), pruritus (30%), musculoskeletal pain (28%),
and urinary tract infection (22%). In Checkmate 142 in MSI-H/dMMR mCRC patients receiving OPDIVO as a single agent (n=74), the most common
adverse reactions (&ge;20%) were fatigue (54%), diarrhea (43%), abdominal pain (34%), nausea (34%), vomiting (28%), musculoskeletal pain
(28%), cough (26%), pyrexia (24%), rash (23%), constipation (20%), and upper respiratory tract infection (20%). In Checkmate 142 in MSI-H/dMMR
mCRC patients receiving OPDIVO with YERVOY (n=119), the most common adverse reactions (&ge;20%) were fatigue (49%), diarrhea (45%), pyrexia
(36%), musculoskeletal pain (36%), abdominal pain (30%), pruritus (28%), nausea (26%), rash (25%), decreased appetite (20%), and vomiting
(20%). In Checkmate 040, the most common adverse reactions (&ge;20%) in patients receiving OPDIVO with YERVOY (n=49), were rash (53%),
pruritus (53%), musculoskeletal pain (41%), diarrhea (39%), cough (37%), decreased appetite (35%), fatigue (27%), pyrexia (27%), abdominal
pain (22%), headache (22%), nausea (20%), dizziness (20%), hypothyroidism (20%), and weight decreased (20%). In Attraction-3, the most
common adverse reactions (&ge;20%) in OPDIVO-treated patients (n=209) were rash (22%) and decreased appetite (21%). In Checkmate 577,
the most common adverse reactions (&ge;20%) in patients receiving OPDIVO (n=532) were fatigue (34%), diarrhea (29%), nausea (23%), rash
(21%), musculoskeletal pain (21%), and cough (20%). In Checkmate 649, the most common adverse reactions (&ge;20%) in patients treated
with OPDIVO in combination with chemotherapy (n=782) were peripheral neuropathy (53%), nausea (48%), fatigue (44%), diarrhea (39%), vomiting
(31%), decreased appetite (29%), abdominal pain (27%), constipation (25%), and musculoskeletal pain (20%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Please see US Full Prescribing Information for OPDIVO and YERVOY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Clinical Trials and Patient Populations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Checkmate 037&ndash;previously treated metastatic melanoma; Checkmate
066-previously untreated metastatic melanoma; Checkmate 067&ndash;previously untreated metastatic melanoma, as a single agent or in combination
with YERVOY; Checkmate 238&ndash;adjuvant treatment of melanoma; Checkmate 816&ndash;neoadjuvant non-small cell lung cancer, in combination
with platinum-doublet chemotherapy; Checkmate 227-previously untreated metastatic non-small cell lung cancer, in combination with YERVOY;
Checkmate 9LA&ndash;previously untreated recurrent or metastatic non-small cell lung cancer in combination with YERVOY and 2 cycles of
platinum-doublet chemotherapy by histology; Checkmate 017&ndash;second-line treatment of metastatic squamous non-small cell lung cancer;
Checkmate 057&ndash;second-line treatment of metastatic non-squamous non-small cell lung cancer; Checkmate 743&ndash;previously untreated
unresectable malignant pleural mesothelioma, in combination with YERVOY; Checkmate 214&ndash;previously untreated renal cell carcinoma,
in combination with YERVOY; Checkmate 9ER&ndash;previously untreated renal cell carcinoma, in combination with cabozantinib; Checkmate
025&ndash;previously treated renal cell carcinoma; Checkmate 205/039&ndash;classical Hodgkin lymphoma; Checkmate 141&ndash;recurrent or
metastatic squamous cell carcinoma of the head and neck; Checkmate 275&ndash;previously treated advanced or metastatic urothelial carcinoma;
Checkmate 274&ndash;adjuvant treatment of urothelial carcinoma; Checkmate 142&ndash; MSI-H or dMMR metastatic colorectal cancer, as a
single agent or in combination with YERVOY; Checkmate 142&ndash;MSI-H or dMMR metastatic colorectal cancer, as a single agent or in combination
with YERVOY; Checkmate 040&ndash;hepatocellular carcinoma, in combination with YERVOY; Attraction-3&ndash;esophageal squamous cell carcinoma;
Checkmate 577&ndash;adjuvant treatment of esophageal or gastroesophageal junction cancer; Checkmate 649&ndash; previously untreated advanced
or metastatic gastric or gastroesophageal junction or esophageal adenocarcinoma</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About the Bristol Myers Squibb and Ono Pharmaceutical Collaboration</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 2011, through a collaboration agreement with
Ono Pharmaceutical Co., Bristol Myers Squibb expanded its territorial rights to develop and commercialize <I>Opdivo</I> globally, except
in Japan, South Korea and Taiwan, where Ono had retained all rights to the compound at the time. On July 23, 2014, Ono and Bristol Myers
Squibb further expanded the companies&rsquo; strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies
&ndash; as single agents and combination regimens &ndash; for patients with cancer in Japan, South Korea and Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About Bristol Myers Squibb</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Bristol Myers Squibb is a global biopharmaceutical
company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more
information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Celgene and Juno Therapeutics are wholly owned
subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics
are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Bristol Myers Squibb Cautionary Statement Regarding
Forward-Looking Statements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>This press release contains &ldquo;forward-looking statements&rdquo;
within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and
commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be,
forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial
results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors
that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and
could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the
statements. Among other risks, there can be no guarantee that the collaboration with Nektar will progress as contemplated in this release
or that NKTR-214, alone or in combination with Opdivo or Opdivo plus Yervoy will receive regulatory approval for the treatment of cancer.
No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the
many risks and uncertainties that affect Bristol Myers Squibb&rsquo;s business and market, particularly those identified in the cautionary
statement and risk factors discussion in Bristol Myers Squibb&rsquo;s Annual Report on Form 10-K for the year ended&nbsp;December 31,
2021, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and
Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except
as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events, changed circumstances or otherwise.&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>Nektar Therapeutics Cautionary Statement Regarding Forward-Looking
Statements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>This press release contains forward-looking statements
which can be identified by words such as: &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;advance&rdquo; and similar
references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the future plans
regarding bempegaldesleukin, approaches for winding down clinical trials and future research efforts. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions
regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions.
Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances
that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated
in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could
cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements
regarding the therapeutic potential of bempegaldesleukin are subject to change; (ii) winding down clinical trials is complicated and time-consuming,
and may incur difficulties and expenses due to a number of factors outside of our control; and (iii) certain other important risks and
uncertainties set forth in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2022. Any
forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of
the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information, future developments or otherwise. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Bristol Myers Squibb</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">media@bms.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">investor.relations@bms.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nektar: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dan Budwick&nbsp;of 1AB</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">973-271-6085</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">dan@1abmedia.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vivian Wu&nbsp;of Nektar Therapeutics<BR>
628-895-0661</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">vwu@nektar.com</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">11<I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  A (H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#T-_'-]%>,
MCVT!B20J=N=Q4''KUKN+>>.ZMXYX6#1R*&4CN#7DOV:2\U62WA&9'E<*#W.2
M<5TO@O63%*=*N&(5B3#N[-W7^OYUY&$Q<_:<M1Z/;U/8QF#@J2G26J5WZ=SN
M3TKS]O'>HJS#[-:X!(Z-_C7?GH:\FTF:&WURVFN&"PI+ERPR .:WQU6<'!0E
M:YCE]*G-3<XWLO\ ,V?^$]U#_GWM?R;_ !J]I7B^]OYKA)(+<".WDE&W/51D
M=^E:_P#PD'AW_GYM_P#OV?\ "EDO],O]+U#[!)%(R6[[MBXQE3[>U*"J7O[:
M_EH.I*GRV]C;SU,WP]XIO-7U1;6>&!$,;-E <Y'U-;NK:O;Z/9F><Y8\1QCJ
MY]!_C7G?AS4(=+U(W<^=BPL !U8\8 IZM=>*=>19IEC:0D+D\(HYPH[G^=84
ML;/V5KWFWH;UL!#VS=K02U- ^/-0S_Q[VH_[Z_QH_P"$\U$_\NUK^3?XUVEE
MI5G86J6\,";5'5@"2?4FN)\<HD>L0!%51]G'"C'\1JJ\<31I\[J$X>6%KU?9
MJF._X3S4?^?>U_)O\:VKCQ1+!X8M=1,<1NKAMJISMX)R?7H*T= @A;0+$M%&
M285R2HKCO%MT;W7%LK<#; !$JKTWMU_H*<Y5J-+GE.[>WJQ0A0KUO9QA91;O
MZ(W/#WBN?5-2^R744,>Y"8RF>2.W)]/Y5T.HW+VFFW-R@!>*-G ;H2!7F^HV
MLGAS7HO+)/E;)4/][U_4$5W^JS)<>&[N:,Y22V9E/L5K7#5IN$X5'[T;F.*H
M4U.$Z:]V5OS.2'CK4CTM;8_0-_C1_P )WJ2D;K6VQ[AA_6HO!#(NM2%RH'D'
M[Q]Q7;7\NG?89OM3P&'8=P8@UA0]O5I\_M+&^(^KT:OL_97V[F1IOBT:C Z+
M;[+M!G9G(8=R*VTN9VC5C;-D@'KBO//",;R>)+8Q@X0,S'T7!']17IM=6"JS
MJT^:3\CDQU&%&KRPVW/,-&_Y&Z#_ *^6_K6AXOTEM/OTU.URD<K@L5_@DZY_
M'^=5](T^]C\50RO9SK&+AB7,9  YYS7H%[9Q7]G+:SKF.1<'V]Q7+0P_M*,X
MO1WT.S$8E4J\)+56LREH6K+K&EK/P)E^25?1O\#UKSC3K5+[6(+61F5)9=I*
M]1UK9TF'4_#VN.C6EQ+;D^7*8XR0R]F'\_SK*BLM5M;L7$%G=+(CED80DX/Y
M5E7J2J1ASQ=T]=/0UP].-*53DDK26FOK^1U__"":=_S\W7_?2_X58CT"VT32
MM3-O+*_FV[ ^80<84^@]ZYK^U/%?I=_^ X_PJYIUYX@NWNH;Y;DPM:RX#0[0
M6V\=NM;PJ4.;W*;3]#GJ4\1R^_537:_FCF]*TZ75;Z.TA8*6&68_PJ.IJ_KN
MCRZ!J,;0._E-AH9>X8=1]:O>#["\M]=22:UGC01,-SQD#M79ZMID6K:?):R\
M$\H_]UNQK&A@_:4&[6E?3Y'1B,:Z>(2O>%M?F5_#^LIK.GK(<">/Y9D'8^OT
M-<IX[_Y#,'_7N/\ T(U4TR/5]"U7S5L;EPIV2JL9(=>^#^HK0\8VMS>ZE;36
MUK/(AMQRL9..2<'T-75JSJX5J2?,FNAG1I0HXM2BURM/K^!T.G7:6'@^WNG^
M[%;!L>IQP*\^L-02UU>._NHS,5<R%0V,L>_YUTFKB]_X173-/AM+AF9%:4+&
M3M Z _C_ "K0\)Z(D.E-+>VJF:9R=LL8RJC@<'IW-.<*E:I"$=.5)[==":<Z
M="G.I+7F;5K]-3F/$.O0:XT#I;-#)%D9+@Y![5M:+?\ VGP7J%JQR]M$ZC_=
M()']1^%=)>Z-975C/ MK C.A"LL8!!['-<!IMOJ5DUW&UC<[)[=X6Q$W7'!Z
M>O\ .E.%6C6YI._,FG9%0J4:]'D@N7E::N_,KZ)I!UJ]:V681%8R^XKGN!_6
MMB\\#7-O:R3174<S(I;9L*DX]#FI/!EE=VVLR//:S1(8"-SH0,Y'K7=L,J1Z
MC%/"8.G4HWFM=18S&U*=:U-Z:=CA/ ^HA+M[ Q)^]4NL@7#$CL3W%=Y7F^@V
M%[8^);=I;2X6-9&0OY9Q@@C.?2O2*Z< Y>RY9=&<N8J/MN:'5!1117<< 444
F4 %%%%  >E':BB@ HHHH **** $-+110 4'I110 =J2BB@3/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  A .0# 2(  A$! Q$!_\0
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M M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>nktr-20220414.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /Ksps7xRiXgOn8uFYHlMOaSIiaPtzJZzuekxt2p1HQmqXyArpu5VNiKer1YG4XMC -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:NKTR="http://nektar.com/20220414" elementFormDefault="qualified" targetNamespace="http://nektar.com/20220414">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://nektar.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="nktr-20220414_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="nktr-20220414_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>nktr-20220414_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>nktr-20220414_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nektar.com/role/Cover" xlink:href="nktr-20220414.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://nektar.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140409764283016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 14,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEKTAR THERAPEUTICS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000906709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3134940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">455 Mission Bay Boulevard South<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">482-5300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NKTR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>ea158456-8k_nektarther_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nktr-20220414.xsd" xlink:type="simple"/>
    <context id="From2022-04-14to2022-04-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2022-04-14</startDate>
            <endDate>2022-04-14</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-04-14to2022-04-14">0000906709</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-04-14to2022-04-14">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-04-14to2022-04-14">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-04-14to2022-04-14">2022-04-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-04-14to2022-04-14">NEKTAR THERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-04-14to2022-04-14">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-04-14to2022-04-14">0-24006</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-04-14to2022-04-14">94-3134940</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-04-14to2022-04-14">455 Mission Bay Boulevard South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-04-14to2022-04-14">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-04-14to2022-04-14">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-04-14to2022-04-14">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-04-14to2022-04-14">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-04-14to2022-04-14">482-5300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-04-14to2022-04-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-04-14to2022-04-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-04-14to2022-04-14">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-04-14to2022-04-14">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-04-14to2022-04-14">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-04-14to2022-04-14">NKTR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-04-14to2022-04-14">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-04-14to2022-04-14">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "%A8Y4JL0B%C,!   B @
M#P   'AL+W=O<FMB;V]K+GAM;(U1T6[", S\E2H?L!:T(0U17D#;D*8-C8GW
MT+K4(HDKQX6-KY_;JAK27O:4W-FZW%T6%^+3@>B4?'D78FYJD6:>IK&HP=MX
M1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\
MG7<P.6/$ SJ4[]ST=P<F\1C0XQ7*W&0FB35=7HCQ2D&LVQ5,SN5F,@SVP(+%
M'WK7F?RTA]@S8@\?5HWD9I:I8(4<I=_H]:UZ/(,N#Z@5>D(GP&LK\,S4-AB.
MG8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H
M YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*
MO8=7LN48<?R>Y0]02P,$%     @ A86.5"0>FZ*M    ^ $  !H   !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0
M!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*
M+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\
M7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7
M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( (6%CE1ED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "%A8Y4)!Z;HJT   #X 0
M&@              @ &?$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " "%A8Y499!YDAD!  #/ P  $P              @ &$$@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #.$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea158456-8k_nektarther.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nektar.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea158456-8k_nektarther.htm">ea158456-8k_nektarther.htm</File>
    <File>ea158456ex99-1_nektarther.htm</File>
    <File>nktr-20220414.xsd</File>
    <File>nktr-20220414_lab.xml</File>
    <File>nktr-20220414_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea158456-8k_nektarther.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ea158456-8k_nektarther.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nktr-20220414_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nktr-20220414_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nktr-20220414.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "NKTR",
   "nsuri": "http://nektar.com/20220414",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea158456-8k_nektarther.htm",
      "contextRef": "From2022-04-14to2022-04-14",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://nektar.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea158456-8k_nektarther.htm",
      "contextRef": "From2022-04-14to2022-04-14",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001213900-22-019858-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-019858-xbrl.zip
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MH^*.^:\/OUYG*V=IOGT"A)N.A5"5$6-,3)5^!P)WX%Z9.J>A4%4B-\YQ1XL
MT,5.>@0<YX/?1\CK8;Z<2F*Q+G?"4XEA8E$K+1Z63AR1WB(;..Z/>RJY&%>&
M;F#"/#S3B&=&D-+Z&OBB;"&%6-K!ZPE5!-'3=@FZN?>[2Y*I-)8(>-FV5+A7
M&K<Z4HUJ89MT$_S>/CT1.\==S;A]U<CN$<:>#NK>Z_P\L8O5[#YB([A'&EK<
M^MJLR?&%C:@^V)/R0F!/CJO"GD R50LZC;:[\&8#KD*A\#U+G!;5F3W&WA\X
M](VJX\#0H$2P(9?0#JP4ST-0>WV-FNJM?P4\?>I85%@RW.FRE@5=6QMT\@Y$
MTOQR9#*G[W7RWO!5O\2K?*FO^B5>!?P;O>KWJ-R1YSVH?Q]@_@3(A@-0@&91
MEG-O1B9#E>0\Z864]Q.V%7;Q9N<URCA,AQJ_5;K @&#T+FLP,"[@TE-<)[O<
M3ND1V?C9+I.3^N[GTZ@T?38@.SD(!,)CG0U\M4?F5IR">9WC@>"'&;;7<B7N
M9"H7#IE]?6<3R.']'N021D8]%D#L*!%7[, BNA>6J2_ZW@=PHHY%#@1X;M?.
MGHV9D*1S'W##(-%J-VEX<-:)6X%?=L#SFN!E!9.![4O2A?56>55/L*QG0P4H
MI ZUQY+)V..V8&%@9(NTFE\O+K-:F9@VQX0C^')?[6IM8*VHOTFE2RR:=,TP
M:J/*Z1MLX+$>M2TF;1;< 7*;\-HX:S6.)FVXVD<V\'5N7 74TG+A@?:Z9,.!
M?^U@0 VLMK[F0154A;"2AZM.>!@#7Q!@%%<T:@VI&CNL2GCI"QYP _0A&(Q6
M9=*(287)'9C/"4/M6BTA/"LAC4(D#5V;2(,H8:RO+4H#*BV51CCFQ\8*1;/#
M,]7U'M :=(H!$N 0%6P2&X_MP(CC<:ZOS0XT$"XP9N-\F5A!K Z1IFOX+S&C
MIA-.RHS634Q)6<E9ASPPP4".B"!1, "$$-8")8\I<J1.?4K.7(?[KL!942>N
M?9^QB2K4SZ:JX/>I3ZC"-'9D+5Q9BVO<(F09(JR2GNN H@@,=F(B%^WV5)\D
M6+$$,T-X!!P=V%PAK&:"K>A.%=(&?08A3>RD69O2D7WW 8$9\O2T,ED\Q'80
MN?JQX<OXW2Z0#":FJ!@K5*<41ZH4%I$ .-7Q;="<B+Y'P?\ >0!J2,@?"U>"
M0A*P:+00[O2Y@?*<L'UYTIQPC:!?N" ],4!R2*")F8.0932CLZGJMI6-UM!&
M:Q,;Q2G#.[)@KASI"I\' W4J"Z<8SW'E/=<566#Q#BT>3"/\[+E>8(=[)3E2
M=<(F?# [C4/PP-"9#,20#Y5-QQ.8<*:V?$*<Y-G29%PM9Z&_A2'-,'D$^N2H
M^56GT4"3'P"H.^[4\1C,@3#8CP5IN0%X!,4/+"1C)>-POL+S:E@'Y@*?;ZHO
M8:R L6V?@NY:P']TM"UP#%3+<(*5KU<'3*$$T#^:$_*!.Q#AK$V7#APQ-KKH
M$-!ESP4Q_S7]S<P&TR,>2#*0+]KZK,O?G/@)L/V)DLU9/ICS"\U8J$0UAG]X
M_I>:>.H0-+#OVN')Q,!3+T6CM7$G0,\6*JG;$W2@5LZ992&RK7><JTB?@P.*
MH@09S>,:L"7I!Q9'<M,U87T-%P6EZ[>HF;!J)G2>1?K>"Q-S$RNSV)#9KJ<V
M76,)HIH_.5LY<&T3(XD,,,$8* /X&E=Y@.@9>H(GR2:./X.2>?#$1]<"%,;8
M:A!($Z(T[@RIQ!7)L($%Z")<_,E&K:H52UE-*W] '56H9GU-SQ<B"A'VF_<E
M:>R@+TF4ZZ<$<-.D UT/L5/4!YEVP7&^S$ (E"A4R:M\05=0$U:-,8 ZY<@Q
M1>0' Q<@;DRRH '/#]Q&SP>F("/U9M8F^OGHZ&P,F2+<Q@7Q^F![)J>.Q$F
M1I);2N9A$@*'#": C@X0HYIFUU,^>'TM<F= )/+N*FT5SJC\:SJVN4ZJ,"!O
M,NV>>M= ,)NII1P/2%CAW$.$H)(RZVMJ[M7AZ2BL4"+#C*WO@U>"!KA8@:0I
MYDP5&"#E<D[?5%.BSE#'+]]%=:$#<(>3:]+^%G(]# 3:QF8D/71/"=/I'!ZC
M68@!-57 !Z BC.T,Y=$"P)!@.& EZL2'%;94SFT>P)[5)AX.\W@#:H69.W1L
M,O(["5,A'$PC"F7R$-JU+UJ-T^S6]L3ZP4<N=T G;.R+P() R6,# W <_Q''
M8G.Q2B(  1,*'- KT!]UFF%J^_(^H .(U^;#L/B8!5["I90&=.]NQIO.C#E$
M9%-'GCY<]#_A<*>>[CE#Q<5R/L::BR55;BAR5DGO[+A.5@[0RZL!V@$\BV(P
M?+< G=:,&UM8LY2OBX)&D <.)G)-R+-*5JD!,X2_B,%QY@<N7GZ"N("K)0NB
M^PDLB\(3C!R!N&-E+?=A\F["9,5;7.7^%B;9$MP5,1".?1R,'<4ZR5-/H80K
MPK= NER 0$%5\>X+K#^3M6$C6!A\M;+$_A L%[/@F%WW60_T0TT!5)A$"R:5
M?2("YX&.2<_%% +"/X3WJ Z! HA6H"+2:0((WX5:7T-%##445G@F?5P?06?/
MP'CZDYS2.P9RTWQ>&?-YAQ.YJQ<*!Y.E.UHY5I[D>]5WV>84#F]P2HSCK_LB
MSQO>E%+^?<5'?6)(<NZB!N2><Q&%OJJ+*,K:JD=39](47*T)2;5^I0-**^0=
M$>'SCYRL4FB4A!?Y,JJ7=HJE;38JE[-Z=,LV8K9<WQ^H [<)**SN#;?(3%:>
M))+Q9"897XU7@BO/4O=1.*06+Z[U1#C92BZTB^GQ<.U5Z*KV=$(\%Z6H]O-T
M51KPT.<^>YWYU[7BFTQ_#9-\:C\P3#S2,&^K$L'JDHT-0+;,0BB)<I[D*/&.
M?X*7_$-H'%[*]B'WJT]+/[ZG6=@#I5#@<!?I1YOH>^0KGIO[A5N>+SO)'1X@
M>];];YG*[%7LH0#V"-YVN4NJ@AK<C&]G1R&=NSAT?6;3,VZE]N'?\8;L.X1P
MNJ[E],<NK6T>G5<OK]JKNCKW3:!;\F+.,%P SRY"?*IN$'K&X;#-M(,V5@!Q
MI$D#J9*^7,;W5T(_!E,;!&%&$X,2@_6IW<7<"!)2[W%$%3!K$CB^N[ZFZ-'
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M?Q68<UDB-);<,7-P!@$IS)[H$+1]*^Y!3V,%_8J!-R4"YI>M"L8'P>@X NJ
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M1J "P4.1-XDYX*\"T7\(QG]FT>-3@IL*M ?PT"D90P-P]<D<N_%8;Y0S9_X
M^%0$AV'\MUH!I".CEC+[==DN63<?YH3OFO@V3>)BEYP=#3N]]1;&(F&!@P^)
M]VCBRU.1%3,R%(E;SV%U,587QS^:^AI8KVEVTFJRE&8@F/P0\T95XI'(^)FT
M!AJ'[/RI#B<M$JNA3SNZ\4>B1/EC@Z$TB<=X$H6@TLG"M<%:916^V1 =?D\9
MH/Y70.'/Z.5$D_B<0'1?98%5ADHX2_2J24.;>"E0_W9*NHX'/Y4_9Z-"%-3"
M8-LS&_H:D+ LHAR;JO %T/9?Y\=/Y$QFOLOYC(TZTR2S8('?1AE)_@JW6/8E
M^#7FGCI_2\RQ6[ L1]&QX^^IMS?@^D:)!7[.:)9I4M5KF6G=1O%U;N:GD;LF
M>=TJU&MM^JW%!]'$6OGQ#[.OJJ/U[O[M;1C:?P%:+[Q6SUY?.-R<'<G#*!;8
M1,9P6><<VK,F>ZQGGD\\BBP4.JRT,&E<KXQ(S\(-AE<@7*SP99Z6I5';A[;$
MZ*D)]RQW(CVBQ)[^KQ?HF^1ZT5+@:E<%$\0XY7E)1(D15^.-N[^COG>&X(0(
M_D^[K7[T=3!^I-YY$_V8WO\STP0V&E:UVR8.].3Y^6]V3M>IW.W5>)4/\<Q$
M$^RS9P&1CNKN'=#T213X8UK"N_*()E!2;/7)/LU:LX AG>UU>Z@)P6B5<UZU
MNZC#FC5AH7>=T@'-/F CX'B@Y_GLZ9-?GYX.2?+F_K,G^[\^O5='^=\DF'+_
M'XQ7XXYMJ9BHCYC^7\0"K.0PVK>^\8(,UO.DAG\+5Z:/:NQ8DB9)EI1T@!_B
M!"PA(=*/H)<0:7L;75I6+=\1IP[Q$]AD)%Z&,-E'Q/K^\D+^>W?9]E_OS"Q<
MW86!G+O-7C\_*_Q:1@.7IZX?K-UL0&_,G6%@HY,HAC:C3HE70IK3-@][?6=E
M\#PY$.\^ZH*KDAVAH9-Z)?.DUKO?V>MT#M5LLG\]X:557"']PP[]J(B9QN(U
MT#2GOF;E@%@PH;%9"VF)J1PMU((T]FXT:2=X[RI+>';B[ZIPP(VCA$_-,9?V
MB+.Y^[) )G#[0;-AI$%N)(UTBW[R1B,]3STRQVCC'T@A3!>8"D<VCKU;@1F,
M&ZP1HBZ; T*]@=%)V--OU9E$L>\W@DL.P(!5DXU2\<F(Z&@V/I?L(-9@R?9>
M><$RR^EV[IWE_(/Z<>[D<]A0[@$D=C A<Q_.UD_E0BY'&&L]8[W;>@$9M7+W
MH., L+Z(= J$O\5_FPVHV@$8%9ORS#826'ZDP22*3'92_4A[897KW?/VJVZ)
M 71/>A4&H,.8-#>#L_/5-&05JF;C:Z6ASRJOZZ(<7Q,AO:^381*MI5.%S)I%
M2<K."X21%G,D$UR1L!V'>F%U>,B%,<S'EB*TBH!WA/U FED4B]FA!OUNJ]/I
MJ) 6._(2$U_M'IWPTS%A[#2!71B,;_TQH3>\UPM2[??8E08RGY,Q^,&?$6K#
M:+PE#:#9\!*[-#9+0T3MZ%^W$?V[57AEI_YD2FH$A_>2W*%G9 N]_R:*Z<W3
M&8%MY/'"7F1Q-->"Y%<D5MM82Q%SXHB#&%%,W"3,)V&46"92&,@MEH%&8VA5
MX9:H;G_OY/LOAAI^+4("7R4U/"L[A@T%=#LX4H<,<K078YFQUF!;@? '1_T*
MPA=(XH5AAO#1G@O1G/Y:\%R,S)17,=M\<)0,]03FMM$P18"P[P]B19;BLT,W
M#WK)=G*J%"]NF9!..M^SDEC>.2]X3YV'>4S1VO;YF'7A(7Q._&%$@@;+E,P)
M..URHLMBTDRA5L+%W2K)2ORH4T3^08"B7,]U<.,;63/S_B#-.&6'?-WD"?L6
M<R 3<T@Y_N7%M$U.?FFI8>8P@4(@\I=@$B1T2] Y$.@4\G6*2"SM?X(06CS1
M)II<C3!8W@)O%ZD?'^:$@CS1LD)+4^9AVV#1JAQ/CQ8 L7M060=PK?8$C _$
M]=&9.?>:C1^7G-3.:VY&#OQN!$4B /H_F"<&O3W%ADNX'(6',59:>;>'A7>M
MOD"@0]A<5!.3*Y(LDE3/$-VPQ@#.&=.I<19[0S\PQVWS,W+DO_+C)&VS.F5M
M$"A2XCH63"$KD1:HPXFV'SE!C2MGX[F5T;)V6BP($?@SG[U:2\$0W\:>H>B4
ME[$<!\CMQ:\@H&K%05VFSB-U!D!)$.Z9!!M^S%(B:@;*.QW- \T@:3;.&->^
M*M%1E[L$^@F3N1^;S"5CFBCB:3Y<K3_,QEXR?0QN&";(XG#C=L;=06AXH\'H
MXRB;3"7 /#*:R202RBM<[(O"22*</'>0^NQ['6L,%S,9$P;JQ(0/HJLK>LI:
MES7N/1,Q:B'D$Z13GUX(_"MM$T]FWC7-BN/UB&:3Q!=ZW5//,C]@GDY2 S&T
M";(/O%%,[V#0./+&\%],M(0;L4R[#,YZ(<*E'\<%;P'_'*5>$8BD(UJTZM/%
M['Y9CL!.XM@:5@-!?!4CS(#?8-G1_X+KLA?% H29 (2I@-L)]HW)ZH,Y!G,/
M9P5M%\(^BT,,SWD#?DB @1">3%,CG)$L,)>,(3^FU8\RDF?/M9Z[N0(L(5(?
M/&B4,2-IZ_%$(Y@W%SYH,Q(Y5,*>F7P=9 N*'5=@ <XGB*)K53C:.4M4?#H>
MD'!/G5E9'TJVD4? "Z!JP"*=Q%XRQPD"ULU&+L0]BQ\YH@$G6JOS]_RD'/I,
MO6MF$2,YSI33EM@(ACSQX"V2F1"(;LFRC5#W)6PM>!'%R=2?$[;ID9>11/7*
M =M<D<$@JQ:&.)2-P<[FT:WF7#1"C)Q5V7'H#0,C(8IFXXI9VQ>CNE<"7O\H
MX_W, :_25F4-["8RP40X<=C>;'?5SKOG;61GF. 3L8W1-:?(.7YDIF(?_A_D
M"=IL/)^T<M)RB+A#X"ZKQM&X8+_1;:C,J*+F, KI8 X.E<)*@-NY+<X@>1$N
M&M%S"*OSH:URO'GT*W =J\;9:Q-+H)@2H0PU4@ XDW:&-#!:2J'ED#!@-<>R
M[!E9]C[HP;#J+TQE68$C6\38>H_56U'X'F&N"\TLZ['ZS0LR_/QWA>"VWWC=
M7:GM;D Y8+  >*PN%W/:YRDT\=%C]<:;:0'2FPA;[Y6"</8K_/)5!PC_2:0M
M47,N?TGF@4D8+[@3!">Q;?(GB'WEJ1YUPC ?K$XG*8PN B<D\SDX3]1^:S*
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M[KF7?KTK7GU63WRS47;%HUV!9?:X2B*,HAZ@A1O;F![":HH0=,&=;9"4=/7
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MBFA7D^V'1'SCD O-Y-H<F;-7RFB%\B2I)6?!A<UUPW"/U-:=4;]%D[3]2[1
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M#>%KT=W]R-EK_EBN(0N6#U"[Y:/3<I,3JS0@7KK\ =SH$*1B]+*__@#:'19
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M(UVW]H![#V]QQOUR[YJU1_X'4$L! A0#%     @ A86.5/1+PN-6%@  E'
M !H              ( !     &5A,34X-#4V+3AK7VYE:W1A<G1H97(N:'1M
M4$L! A0#%     @ A86.5,"U5=.=0@  >$T! !T              ( !CA8
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8;6Q02P4&      4 !0!8 0  A&\

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
